drugset / Trial / NCT01192399

Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

NCT01192399

Phase 2 Completed 29 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.

Timeline

Start
2007-11
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 900 mg Intravenous